GLOBAL VIRUS NETWORK (GVN) ADDS SANOFI PASTEUR TO GVN HEALTHCARE & PHARMA CENTERS OF EXCELLENCE COALITION

The Partnership Focuses on Training The Next Generation of Virus Researchers to Safeguard Mankind from Current and Future Threats

Baltimore, Maryland, USA, March 23, 2021: The Global Virus Network (“GVN”), the world’s leading coalition of virologists combatting current and emerging pandemic viral threats and viral causes of disease through international collaborative research response, by training the next generation of virologists and through education and advocacy, announced Sanofi Pasteur, the vaccines global business unit of Sanofi, as its latest member of the GVN Healthcare and Pharma Center of Excellence Coalition, a groundbreaking, pioneering and collaborative strategic initiative that brings together and harnesses the expertise and resources of the world’s leading pharmaceutical companies to lead the war against viruses that pose a clear and present threat to public health and mankind.

The announcement was jointly made by Christian Bréchot, MD, PhD, President of the GVN, Associate Vice President for International Partnerships and Innovation at University of South Florida (USF), and Professor, Division of Infectious Disease, Department of Internal Medicine at the USF Health Morsani College of Medicine, the GVN Southeast U.S. Regional Headquarters,  Jim Tartaglia, PhD, Vice-President R&D, Sanofi Pasteur and Robert Gallo, MD, The Homer & Martha Gudelsky Distinguished Professor in Medicine, Co-Founder and Director of the institute of Human Virology (IHV) at the University of Maryland School of Medicine, a GVN Center of Excellence, and Co-Founder and International Scientific Advisor of the GVN.

The current pandemic, the proliferation of other viral threats such as Ebola, dengue, Zika or yellow fever as well as the interplay between viruses such as HTLV, HPV, HBV and HCV with cancer, are yet other examples of the critical need to pool global resources and urgently address viral threats.  With partners such as Sanofi Pasteur, the GVN is tightly connected to public and private sector entities to develop effective and sustainable scientific solutions to address viral threats and viral causes of disease.

“I am pleased to announce that the GVN is launching our Healthcare and Pharma Center of Excellence Coalition to bring industry partners together in a collaborative, consequential and meaningful way,” said Dr. Bréchot.  “Pharmaceutical industry leaders, such as Sanofi Pasteur and other coalition members such as Abbott, add tremendous value to the field of virology with vast resources towards training and research and development, as well as a commitment to advance scientific data.”

The international business community in general, and the global pharmaceutical industry, are essential to effectively stem the spread of viral diseases worldwide.  Such partners are critical in preparedness against potential pandemics and in stopping the spread of viruses as they appear.  Viruses, viral disease and epidemics and the resultant health problems know no boundaries and spread rapidly beyond national borders causing fear, panic and uncertainty in addition to untold and potentially devastating economic and social consequences.  As we well know from the current pandemic, businesses and corporations throughout the world are neither prepared nor immune and, for this reason, must collaborate, partner and work with organizations such as the World Health Organization and the Global Virus Network to mitigate, be prepared for and respond to viruses, viral disease and epidemics that are becoming far more commonplace, dangerous and harmful.

“Sanofi Pasteur is a world leader in influenza and pediatric and booster vaccines and the largest supplier of polio injectable vaccines worldwide,” said Dr. Tartaglia. “We are dedicated to supporting people’s well-being through world-class collaborations that span major universities, research institutes, government bodies, biotechnology companies and contract research organizations.  The GVN provides a unique platform for our company’s researchers to collaborate with top global experts and advance, research and training opportunities.  The current pandemic has re-enforced the need for such collaboration and we are excited to work with the GVN to expand these efforts.”

“We look forward to growing GVN’s industry partnerships with organizations such as Sanofi and Abbott as they are interested in a direct dialogue and collaborative partnership with scientists at the leading edge of viral research and drug and vaccine development,” said Dr. Gallo.  “Our partnerships help train the next generation of virologists to understand what they need to do as scientists working in the industry.  Should these researchers decide to pursue a career in academia and want to see some of their discoveries developed into a product, they will have a good idea about what an industry partner needs. Further, the Coalition partnership will equip candidates with the entrepreneurial spirit that will enable them to pursue a promising career in academia and/or industry.”

The GVN is a global authority and resource for the identification and investigation, interpretation and explanation, control and suppression, of viral diseases posing threats to mankind.  It enhances the international capacity for reactive, proactive and interactive activities that address mankind-threatening viruses and addresses a global need for coordinated virology training through scholarly exchange programs for recruiting and training young scientists in human and animal virology.  The GVN also serves as a resource to governments and international organizations seeking advice about viral disease threats, prevention or response strategies, and GVN advocates for research and training on virus infections and their many disease manifestations.

About the Global Virus Network (GVN)

The Global Virus Network (GVN) is essential and critical in the preparedness, defense and first research response to emerging, existing and unidentified viruses that pose a clear and present threat to public health, working in close coordination with established national and international institutions. It is a coalition comprised of eminent human and animal virologists from 62 Centers of Excellence and 11 Affiliates in 34 countries worldwide, working collaboratively to train the next generation, advance knowledge about how to identify and diagnose pandemic viruses, mitigate and control how such viruses spread and make us sick, as well as develop drugs, vaccines and treatments to combat them. No single institution in the world has expertise in all viral areas other than the GVN, which brings together the finest medical virologists to leverage their individual expertise and coalesce global teams of specialists on the scientific challenges, issues and problems posed by pandemic viruses. The GVN is a non-profit 501(c)(3) organization. For more information, please visit www.gvn.org. Follow us on Twitter @GlobalVirusNews.

Media Contact:
Nora Samaranayake, GVN
410-706-1966
[email protected]

Global Virus Network (GVN) Adds Renowned Institut Pasteur Korea (IPK) to Combat Viral Diseases

Baltimore, Maryland, USA, March 22, 2021: The Global Virus Network (GVN), representing 62 Centers of Excellence and 11 Affiliates in 34 countries comprising foremost experts in every class of virus causing disease in humans, and the Institut Pasteur Korea (IPK) announced today the addition of the IPK as  GVN’s newest Center of Excellence.

“We are pleased to strengthen GVN’s presence in Asia with the terrific addition of IPK,” said Christian Bréchot, MD, PhD, who is President of the GVN and Professor at the University of South Florida.  “As a member of the Institut Pasteur International Network (IPIN), IPK has excellent opportunities for scientific cooperation with 31 other IPIN members located in 25 countries, in addition to the Global Virus Network’s reach.”

The Institut Pasteur Korea (IPK) is an international research institute focused on addressing global health issues with a combination of cutting-edge approaches in order to understand disease mechanisms and develop new treatments. By promoting multi-disciplinary projects, IPK is at the forefront of drug discovery and contributes to Korea’s future scientific resources through research, education, and technological innovation.  The latest GVN Center is led by Youngmee Jee, MD, PhD, Chief Executive Officer of the Institut Pasteur Korea (IPK) and Special Advisor to the Prime Minister in health and Special Representative for Health Diplomacy, Korea Foundation.

“IPK is pleased to join our South Korean colleagues at the International Vaccine Institute (IVI) as a Center of Excellence of the GVN,” said Dr. Jee. “We look forward to contributing to the GVN Task Forces, such as GVN’s Coronavirus Task Force, leveraging translational technology with interdisciplinary research efforts, establishing exchange programs, engaging in training, participating in prominent GVN meetings and expanding international collaborative projects with the GVN on emerging infectious diseases.”

IPK combines front-line biology, IT, and chemistry, with innovative cell-based drug discovery platforms that identify novel molecular targets for potential new therapies to treat diseases. With world-class drug discovery capabilities and a talented team drawn from all over the world, IPK scientists aim to uncover various physiological and pathological processes to devise new strategies for diagnosing, preventing, and treating infectious diseases. IPK currently focuses on global infectious diseases that represent today’s health challenges, such as emerging zoonotic and vector-borne diseases such as SARS-CoV2, MERS-CoV, Severe Fever with Thrombocytopenia Syndrome (SFTS), Zika virus, Dengue virus, and Ebola virus, as well as hepatitis viruses (B, C, D, and E), influenza, and has a plan to establish a comprehensive platform for therapeutics research on emerging viral diseases (Disease X).

“South Korea, and in particular IPK and IVI, are instrumental in expanding not just GVN’s reach, but unparalleled expertise and commitment to drive scientific truth above all else,” said Robert Gallo, MD, The Homer & Martha Gudelsky Distinguished Professor in Medicine, Co-Founder and Director of the Institute of Human Virology (IHV) at the University of Maryland School of Medicine, a GVN Center of Excellence, and Co-Founder and International Scientific Advisor of the GVN.

About the Global Virus Network (GVN)

The Global Virus Network (GVN) is essential and critical in the preparedness, defense and first research response to emerging, existing and unidentified viruses that pose a clear and present threat to public health, working in close coordination with established national and international institutions. It is a coalition comprised of eminent human and animal virologists from 62 Centers of Excellence and 11 Affiliates in 34 countries worldwide, working collaboratively to train the next generation, advance knowledge about how to identify and diagnose pandemic viruses, mitigate and control how such viruses spread and make us sick, as well as develop drugs, vaccines and treatments to combat them. No single institution in the world has expertise in all viral areas other than the GVN, which brings together the finest medical virologists to leverage their individual expertise and coalesce global teams of specialists on the scientific challenges, issues and problems posed by pandemic viruses. The GVN is a non-profit 501(c)(3) organization. For more information, please visit www.gvn.org. Follow us on Twitter @GlobalVirusNews

About the Institut Pasteur Korea (IPK)

Institut Pasteur Korea (IPK) is an infectious disease-focused research institute located in the Rep. of Korea. To address the unmet global health issues, the talented team of IPK drawn from worldwide utilizes the proprietary cell-based screening platforms to understand disease mechanisms and accelerate the new therapeutics discovery. IPK is a member of the Institut Pasteur International Network (IPIN), constituting 32 member institutes in 25 countries across the five continents, where it plays a key role in driving early drug discovery. By providing fundamental technologies to bridge between Korean and international bio-pharma science and promoting multi-disciplinary projects, IPK stands at the forefront of drug discovery research that contributes to Korea’s scientific, intellectual, and technical resources. (www.ip-korea.org)

Media Contact:
Nora Samaranayake, GVN
410-706-1966
[email protected]

Jieun Kim, IPK
+82-31-8018-8041
[email protected]

Philanthropist Donates US$1 Million to Global Virus Network: Anonymous Gift Will Support Educational & Training Initiatives

Largest Gift In The Organization’s History Coincides With The Tenth Anniversary of the Founding of the Global Virus Network

Baltimore, Maryland, USA, March 2, 2021: The Global Virus Network (GVN), a coalition of the world’s leading medical virology research centers working to prevent illness and death from viral disease, today announced the donation of US$1 million to support GVN’s Academy, an initiative that fosters global collaborations by providing training and mentoring programs for rising junior virologists.  With the new funds, GVN launches the GVN Postdoctoral Fellowship Program and the GVN Rising Star Program.  The charitable contribution is especially meaningful as the GVN marks ten years since top virologists from more than a dozen countries ratified their participation in, and support of, the then newly created GVN at the inaugural meeting held March 1-3, 2011 at the Embassy of Italy in Washington, D.C.

“We are extremely grateful for the philanthropist’s generous donation to advance GVN’s mission, particularly in helping to prepare mankind for future viral threats through international, post-doctoral fellowship programs and education initiatives,” said Dr. Christian Bréchot, President of the GVN, Associate Vice President for International Partnerships and Innovation at University of South Florida (USF), and Professor, Division of Infectious Disease, Department of Internal Medicine at the USF Health Morsani College of Medicine, the GVN Southeast U.S. Regional Headquarters.  “The donation is especially meaningful as GVN marks ten years since its inception.  As GVN’s founders noted from the beginning, gaining experience through academia will help translate the next-generation virologists’ concepts into practical solutions to meet the global, public-health needs of the future.”

During the inaugural meeting ten years ago, GVN members identified a global shortage of rising virologists in basic, clinical and translational research, particularly in low income countries.   Since then, GVN senior virologists have committed to sharing their invaluable expertise with junior virologists through mentorship and intensive training at the GVN to better prepare the next generation against global viral threats.

“As if it wasn’t already clear enough when we first created the GVN, this current pandemic again highlights the importance of funding science and the next generation of virologists in an effort to stay ahead of deadly viral pandemics,”  said Dr. Robert Gallo, The Homer & Martha Gudelsky Distinguished Professor in Medicine, Co-Founder and Director of the institute of Human Virology (IHV) at the University of Maryland School of Medicine, a GVN Center of Excellence, and Co-Founder and International Scientific Advisor of the GVN.  “Scientific research challenges such as the evolving nature of SARS-CoV-2 and developing an effective preventive HIV vaccine candidate abound.  It is incumbent upon my colleagues and me to cultivate an environment to advance and train burgeoning researchers, and to prepare them to take collective responsibility for current and future viral threats.  We are most grateful to our donor for giving us a significant opportunity to do just this.”

The GVN Postdoctoral Fellowship Training Program will train two postdoctoral researchers during a two-year term with the option to rotate among two GVN Centers of Excellence.  Participants of the program will engage in GVN annual and regional meetings during their two-year term, exposing them to top virology experts and cutting-edge research initiatives.  Fellows may also collaborate with GVN’s growing list of industry partners.

The GVN Rising Star Program will mentor 15 bright, junior scientists over the course of two years and match each mentee with a GVN senior virologist to provide one-on-one research and career guidance.  Participants of the program will also engage in the elite GVN annual and regional meetings.

“Like all of my colleagues at the GVN, mentors have helped shape my career,” said Dr. Sharon Lewin, Director of The Peter Doherty Institute for Infection and Immunity and Director of Doherty’s GVN Center of Excellence.  “I am pleased to support these terrific GVN mentorship programs and look forward to fostering an environment of support and opportunity to guide and inspire career paths of early investigators.  I would also like to congratulate the GVN on ten years of making a real global impact, including building collaborative research alliances, advancing the field of virology and educating governments, public health organizations and the public at large on current and future viral threats.”

About the Global Virus Network (GVN)
The Global Virus Network (GVN) is essential and critical in the preparedness, defense and first research response to emerging, exiting and unidentified viruses that pose a clear and present threat to public health, working in close coordination with established national and international institutions. It is a coalition comprised of eminent human and animal virologists from 61 Centers of Excellence and 11 Affiliates in 34 countries worldwide, working collaboratively to train the next generation, advance knowledge about how to identify and diagnose pandemic viruses, mitigate and control how such viruses spread and make us sick, as well as develop drugs, vaccines and treatments to combat them. No single institution in the world has expertise in all viral areas other than the GVN, which brings together the finest medical virologists to leverage their individual expertise and coalesce global teams of specialists on the scientific challenges, issues and problems posed by pandemic viruses. The GVN is a non-profit 501(c)(3) organization. For more information, please visit www.gvn.org. Follow us on Twitter @GlobalVirusNews.

Media Contacts:
GVN
Nora Samaranayake
410-706-1966
[email protected]